Literature DB >> 27646940

How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma.

Ignace B Vergote1, Els Van Nieuwenhuysen1, Adriaan Vanderstichele1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27646940     DOI： 10.1200/JCO.2016.69.7458

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

Review 1.  Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.

Authors:  Ashley L Cole; Anna E Austin; Ryan P Hickson; Matthew S Dixon; Emma L Barber
Journal:  Cancer Epidemiol       Date:  2018-05-25       Impact factor: 2.984

2.  Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.

Authors:  Larissa A Meyer; Weiguo He; Charlotte C Sun; Hui Zhao; Alexi A Wright; Rudy S Suidan; Joseph Dottino; J Alejandro Rauh-Hain; Karen H Lu; Sharon H Giordano
Journal:  Gynecol Oncol       Date:  2018-06-29       Impact factor: 5.482

3.  Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

Authors:  Sarah L Coleridge; Andrew Bryant; Sean Kehoe; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2021-02-05

4.  Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

Authors:  Sarah L Coleridge; Andrew Bryant; Thomas J Lyons; Richard J Goodall; Sean Kehoe; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2019-10-31

Review 5.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

6.  Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study.

Authors:  Alexander Melamed; Günther Fink; Alexi A Wright; Nancy L Keating; Allison A Gockley; Marcela G Del Carmen; John O Schorge; J Alejandro Rauh-Hain
Journal:  BMJ       Date:  2018-01-03

7.  Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.

Authors:  Myong Cheol Lim; Heong Jong Yoo; Yong Jung Song; Sang Soo Seo; Sokbom Kang; Sun Ho Kim; Chong Woo Yoo; Sang Yoon Park
Journal:  J Gynecol Oncol       Date:  2017-07       Impact factor: 4.401

8.  Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.

Authors:  Lijuan Yang; Bo Zhang; Guangyang Xing; Jingran Du; Bin Yang; Qianqian Yuan; Yongxiu Yang
Journal:  PLoS One       Date:  2017-10-23       Impact factor: 3.240

9.  Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.

Authors:  Xiaoli He; Li Wei; Rui Li; Shuang Jing; Linlin Jia; Danwei Ji; Yali Li; Yue Wang; Yongxia Zhu
Journal:  BMC Cancer       Date:  2021-06-27       Impact factor: 4.430

10.  Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.

Authors:  Sarah L Coleridge; Andrew Bryant; Sean Kehoe; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2021-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.